首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency
Authors:James R Corte  Wu Yang  Tianan Fang  Yufeng Wang  Honey Osuna  Amy Lai  William R Ewing  Karen A Rossi  Joseph E Myers  Steven Sheriff  Zhen Lou  Joanna J Zheng  Timothy W Harper  Jeffrey M Bozarth  Yiming Wu  Joseph M Luettgen  Dietmar A Seiffert  Mimi L Quan  Patrick YS Lam
Institution:1. Bristol-Myers Squibb Company, Research and Development, 350 Carter Road, Hopewell, NJ 08540, United States;2. Bristol-Myers Squibb Company, Research and Development, US Rt. 206 & Province Line Road, Princeton, NJ 08540, United States;3. Bristol-Myers Squibb Company, Research and Development, 311 Pennington-Rocky Hill Road, Pennington, NJ 08543-2130, United States
Abstract:Optimization of macrocyclic inhibitors of FXIa is described which focused on modifications to both the macrocyclic linker and the P1 group. Increases in potency were discovered through interactions with a key hydrophobic region near the S1 prime pocket by substitution of the macrocyclic linker with small alkyl groups. Both the position of substitution and the absolute stereochemistry of the alkyl groups on the macrocyclic linker which led to improved potency varied depending on the ring size of the macrocycle. Replacement of the chlorophenyltetrazole cinnamide P1 in these optimized macrocycles reduced the polar surface area and improved the oral bioavailability for the series, albeit at the cost of a decrease in potency.
Keywords:Factor XIa inhibitors  FXIa  Activated partial thromboplastin time  aPTT  Thrombosis
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号